In the second post of the day on overcoming immunosuppression and a hostile tumour microenvironment, we take an extended look at the TIGIT and adenosine pathways through the lens of a company active in both of these niches.
What are they doing and, importantly, why are they taking a particular approach?
Where might they also be going in the future?
In our latest expert interview we offer not one, but two, biotech executives from the context of the science and biology driving their commercial strategy.
With the latest announcement yesterday that their key phase 2 trial will continue and data to be presented at an updated medical meeting, there’s a lot to learn and some key pointers to think about.